June 24, 2016
Teijin Pharma will work to thwart generic erosions as much as possible for its gout and hyperuricemia treatment Feburic (febuxostat), which will go off patent in Japan in 2019, through indication expansions, President Hiroshi Uno said on June 22. Mr...read more